Total revenues were $55.9 million in 4Q26 and $238.3 million in FY26
ROSARIO, Argentina--(BUSINESS WIRE)--September 14, 2026--
Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter ended June 30, 2026. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.
Presentation of Results
In January 2026, the Company's Pro Farm Group $(PFG)$ business was subject to a foreclosure auction. For accounting purposes, PFG has been classified as discontinued operations. The Company disputes the acceleration of the relevant notes and the foreclosure process, which remain subject to ongoing legal proceedings. Accordingly, unless otherwise indicated, the financial results discussed below reflect the Company's continuing operations for all periods presented, and prior-year amounts have been recast to exclude the PFG business.
Financial & Business Highlights
-- Revenues were $55.9 million in 4Q26, broadly stable year-over-year, as
36% growth in Crop Nutrition offset lower Crop Protection revenues and
the impact of the Seeds business reconfiguration. FY26 revenues were
$238.3 million, down 18%, with approximately half of the decline
attributable to the now substantially completed reconfiguration of the
Seeds business and the associated reduction in HB4-related activities.
-- Gross profit was $12.7 million in 4Q26, compared to $13.6 million in
4Q25, including a $4.0 million non-recurring inventory adjustment arising
from an updated assessment of inventory obsolescence. The impact of this
adjustment masked improved performance across several core product
categories during the quarter. For FY26, gross profit was $82.9 million,
down 21%, with improved performance in several core product categories
offset by lower contribution from inoculants and higher inventory
obsolescence charges.
-- SG&A expenses declined by $4.9 million in 4Q26, a 19% year over year
reduction, and $22.5 million in FY26 -- representing a 24% reduction
versus the previous fiscal year. These reductions reflect the cumulative
impact of the cost actions implemented during the year.
-- Net loss from continuing operations improved to $31.8 million in 4Q26
from $54.4 million in 4Q25, while Adjusted EBITDA1 improved $10.1 million
from negative $9.6 million to positive $0.6 million, mainly supported by
the materially lower operating expense base. For FY26, net loss from
continuing operations was $54.4 million compared to $49.1 million in
FY25, while Adjusted EBITDA was $25.5 million compared to $28.9 million
(1) Please refer to the "Use of non IFRS financial information" section at
this end of this document on our use of Adjusted EBITDA and its reconciliation
to the most comparable IFRS financial measure.
Management Review
Mr. Federico Trucco, Bioceres' Chief Executive Officer, commented: "Fiscal 2026 was a challenging year for Bioceres, marked by the ongoing litigation with certain of our creditors and the resulting business consequences, as we have discussed in our previous reports. Against that backdrop, our priorities have been to focus the business on our core capabilities, reduce our cost structure and strengthen operating discipline. Fourth-quarter results provide encouraging evidence of progress. Revenues from continuing operations were broadly stable year-over-year, with improved performance across several of our core product categories. At the same time, the cost actions implemented throughout the year resulted in a materially lower expense base, allowing us to return to positive Adjusted EBITDA.
"We have now substantially completed the nearly two-year reconfiguration of our Seed business and concluded an external strategic assessment of our continuing operations. That work has provided a clear roadmap for the next phase of the business, including rationalizing our portfolio and go-to market channels, revisiting some of our commercial policies and strategic relationships and re-aligning our R&D&R investments with defined financial objectives, while continuing to explore further efficiencies on the OPEX front.
"These actions are also beginning to translate into improved portfolio profitability, although the benefits are not yet fully reflected in reported gross margin as we work through the portfolio and commercial transitions described above. The performance of several of our core product categories gives us confidence in the direction of these initiatives and their potential to support stronger and more consistent profitability.
"As we enter fiscal 2027, our focus remains on improving the performance and cash generation of our continuing businesses, maintaining cost and working-capital discipline, and actively addressing the Company's capital structure and liquidity position. We believe the actions taken during fiscal 2026 have established a more focused operating base from which to move forward."
Key Financial Metrics
Table 1: 4Q26 & FY26 Key Financial Metrics
(In millions of U.S. dollars) 4Q25 4Q26 %CHANGE FY25 FY26 %CHANGE
------------------------------ ----- ----- -------- ----- ----- --------
Revenue by Segment
------------------------------ ----- ----- -------- ----- ----- --------
Crop Protection 29.8 27.7 -7% 147.1 123.7 -16%
------------------------------ ----- ----- -------- ----- ----- --------
Seed and Integrated Products 8.4 4.8 -43% 63.9 37.7 -41%
------------------------------ ----- ----- -------- ----- ----- --------
Crop Nutrition 17.3 23.5 36% 78.5 77.0 -2%
------------------------------ ----- ----- -------- ----- ----- --------
Total Revenue 55.4 55.9 1% 289.4 238.3 -18%
------------------------------ ----- ----- -------- ----- ----- --------
Gross Profit 13.6 12.7 -6% 105.0 82.9 -21%
------------------------------ ----- ----- -------- ----- ----- --------
Gross Margin 24.6% 22.8% -178 bps 36.3% 34.8% -151 bps
------------------------------ ----- ----- -------- ----- ----- --------
Operating Expenses 28.5 23.9 16% 103.2 82.3 20%
------------------------------ ----- ----- -------- ----- ----- --------
4Q25 4Q26 %CHANGE FY25 FY26 %CHANGE
------------------------ ------ ------ ------- ------ ------ -------
GAAP Net income or loss (54.4) (31.8) 42% (49.1) (54.4) -11%
------------------------ ------ ------ ------- ------ ------ -------
Adjusted EBITDA (9.6) 0.6 106% 28.9 25.5 -12%
------------------------ ------ ------ ------- ------ ------ -------
4Q26 & FY26 Summary:
Revenues from continuing operations were $55.9 million in 4Q26, broadly unchanged from the prior-year quarter, as growth in Crop Nutrition offset lower Crop Protection revenues and the impact of the Seeds business reconfiguration. Gross profit was $12.7 million compared to $13.6 million in 4Q25, as improved performance across several core product categories was offset by higher inventory obsolescence charges.
SG&A expenses declined 19% in the quarter, reflecting reductions in both fixed and variable expenses following cost actions implemented throughout the year. Net loss from continuing operations improved to $31.8 million from $54.4 million in 4Q25, while Adjusted EBITDA improved to $0.6 million from negative $9.6 million.
For FY26, revenues from continuing operations were $238.3 million, down 18%, with approximately half of the decline attributable to the reduction in Seeds and HB4-related activities. Gross profit declined 21% to $82.9 million, with the largest decline in Crop Nutrition, reflecting a lower contribution from the Syngenta agreement, partially offset by improved contribution from microbeaded fertilizers. SG&A expenses declined 24% to $71.2 million, outpacing the reduction in revenues and reflecting the cost actions implemented during the year. Net loss from continuing operations was $54.4 million compared to $49.1 million in FY25, while Adjusted EBITDA was $25.5 million compared to $28.9 million.
For a full version of Bioceres Crop Solutions' fiscal fourth quarter 2026 and full year 2026 earnings release, click here.
Fiscal Fourth Quarter and Fiscal Year 2026 Earnings Conference Call
Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company's website.
To access the call, please use the following information:
Date: Tuesday, September 15, 2026 Please dial in 5-10 minutes prior
to the start time to register and
join. The conference call will be
broadcast live and available via
the investor relations section of
the company's website here.
Time: 8:30 a.m. EDT, 5:30 a.m. PDT
US Toll Free dial-in number:
1-833-461-5787
International dial-in numbers:
Click here
Meeting ID: 858 577 061
Webcast: Click here
About Bioceres Crop Solutions Corp.